Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15
Capricor Therapeutics (NASDAQ: CAPR) will announce its financial achievements for the fourth quarter and full year 2022 on March 15, 2023, following the market close. The company is expected to discuss its developments regarding CAP-1002, its leading candidate for treating Duchenne muscular dystrophy, currently in late-stage clinical trials. A conference call is scheduled for 4:30 p.m. ET on the same day to discuss the results and recent corporate updates. Investors can access the live webcast and replay through the company’s website.
- Upcoming conference call scheduled for March 15, 2023, provides a platform for updated financial results.
- Focus on CAP-1002 in late-stage clinical development indicates potential growth and market interest.
- None.
-Company to Host Conference Call, March 15, 2023, at 4:30 p.m. ET-
SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial results for the fourth quarter and full year ended December 31, 2022, after the market close on Wednesday, March 15, 2023. Management will then host a webcast and conference call at 4:30 p.m. ET on March 15.
| Title: | Capricor Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update Conference Call and Webcast |
| Date: | Wednesday, March 15, 2023 |
| Time: | 4:30 p.m. ET |
| Conference Call Details: | Toll-Free: 1-877-451-6152 International: 1-201-389-0879 Conference ID: 13736398 |
| Webcast: | Webcast Link - Click Here |
A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company’s website.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor’s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy. Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor’s focus is on developing exosomes capable of delivering nucleic acids, including mRNA, as well as proteins to treat or prevent a variety of diseases. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and Twitter.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; the ability to achieve product milestones and to receive milestone payments from commercial partners; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams and revenue projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on March 11, 2022 and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 as filed with the Securities and Exchange Commission on November 10, 2022. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricor’s exosome-based candidates have been approved for clinical investigation.
For more information, please contact:
Capricor Media Contact:
Raquel Cona
KCSA Strategic Communications
rcona@kcsa.com
212.896.1204
Capricor Investor Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
617.435.6602
Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
310.358.3200
FAQ
When will Capricor Therapeutics announce its 2022 financial results?
What is the significance of the CAP-1002 development for Capricor Therapeutics?
What time is the Capricor Therapeutics conference call on March 15, 2023?
How can investors access the Capricor Therapeutics conference call?
